These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 27915266)

  • 1. Systematic ajmaline challenge in patients with long QT 3 syndrome caused by the most common mutation: a multicentre study.
    Hohmann S; Rudic B; Konrad T; Duncker D; König T; Tülümen E; Rostock T; Borggrefe M; Veltmann C
    Europace; 2017 Oct; 19(10):1723-1729. PubMed ID: 27915266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further Insights in the Most Common SCN5A Mutation Causing Overlapping Phenotype of Long QT Syndrome, Brugada Syndrome, and Conduction Defect.
    Veltmann C; Barajas-Martinez H; Wolpert C; Borggrefe M; Schimpf R; Pfeiffer R; Cáceres G; Burashnikov E; Antzelevitch C; Hu D
    J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27381756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term flecainide therapy in type 3 long QT syndrome.
    Chorin E; Taub R; Medina A; Flint N; Viskin S; Benhorin J
    Europace; 2018 Feb; 20(2):370-376. PubMed ID: 28339995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilsicainide Administration Unmasks a Phenotype of Brugada Syndrome in a Patient with Overlap Syndrome due to the E1784K SCN5A Mutation.
    Hasebe H; Yokoya T; Murakoshi N; Kurebayashi N
    Intern Med; 2020 Jan; 59(1):83-87. PubMed ID: 31484910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual phenotypic transmission in Brugada syndrome.
    Hermida JS; Arnalsteen-Dassonvalle E; Kubala M; Mathiron A; Traulle S; Anbazhagan K; Hermida A; Rochette J
    Arch Cardiovasc Dis; 2013; 106(6-7):366-72. PubMed ID: 23810369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome.
    Makita N; Behr E; Shimizu W; Horie M; Sunami A; Crotti L; Schulze-Bahr E; Fukuhara S; Mochizuki N; Makiyama T; Itoh H; Christiansen M; McKeown P; Miyamoto K; Kamakura S; Tsutsui H; Schwartz PJ; George AL; Roden DM
    J Clin Invest; 2008 Jun; 118(6):2219-29. PubMed ID: 18451998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lidocaine attenuation testing: An in vivo investigation of putative LQT3-associated variants in the SCN5A-encoded sodium channel.
    Anderson HN; Bos JM; Kapplinger JD; Meskill JM; Ye D; Ackerman MJ
    Heart Rhythm; 2017 Aug; 14(8):1173-1179. PubMed ID: 28412158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of the sodium-channel blocker challenge in Brugada syndrome.
    Therasse D; Sacher F; Babuty D; Mabo P; Mansourati J; Kyndt F; Redon R; Schott JJ; Barc J; Probst V; Gourraud JB
    Int J Cardiol; 2017 Oct; 245():178-180. PubMed ID: 28784436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myotonic dystrophy type 1 mimics and exacerbates Brugada phenotype induced by Nav1.5 sodium channel loss-of-function mutation.
    Pambrun T; Mercier A; Chatelier A; Patri S; Schott JJ; Le Scouarnec S; Chahine M; Degand B; Bois P
    Heart Rhythm; 2014 Aug; 11(8):1393-400. PubMed ID: 24768612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flecainide provocation reveals concealed brugada syndrome in a long QT syndrome family with a novel L1786Q mutation in SCN5A.
    Kanters JK; Yuan L; Hedley PL; Stoevring B; Jons C; Bloch Thomsen PE; Grunnet M; Christiansen M; Jespersen T
    Circ J; 2014; 78(5):1136-43. PubMed ID: 24599044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yield and Pitfalls of Ajmaline Testing in the Evaluation of Unexplained Cardiac Arrest and Sudden Unexplained Death: Single-Center Experience With 482 Families.
    Tadros R; Nannenberg EA; Lieve KV; Škorić-Milosavljević D; Lahrouchi N; Lekanne Deprez RH; Vendrik J; Reckman YJ; Postema PG; Amin AS; Bezzina CR; Wilde AAM; Tan HL
    JACC Clin Electrophysiol; 2017 Dec; 3(12):1400-1408. PubMed ID: 29759671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential calcium sensitivity in Na
    Abdelsayed M; Baruteau AE; Gibbs K; Sanatani S; Krahn AD; Probst V; Ruben PC
    J Physiol; 2017 Sep; 595(18):6165-6186. PubMed ID: 28734073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ventricular arrhythmia during ajmaline challenge for the Brugada syndrome.
    Dobbels B; De Cleen D; Ector J
    Europace; 2016 Oct; 18(10):1501-1506. PubMed ID: 26941343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant response to ajmaline challenge in SCN5A mutation carriers: experience from a large familial study.
    Gandjbakhch E; Fressart V; Duthoit G; Marquié C; Deharo JC; Pousset F; Hebert JL; Simon F; Himbert C; Klug D; Charron P; Hidden-Lucet F
    Int J Cardiol; 2014 Mar; 172(1):256-8. PubMed ID: 24476701
    [No Abstract]   [Full Text] [Related]  

  • 15. High prevalence of concealed Brugada syndrome in patients with atrioventricular nodal reentrant tachycardia.
    Hasdemir C; Payzin S; Kocabas U; Sahin H; Yildirim N; Alp A; Aydin M; Pfeiffer R; Burashnikov E; Wu Y; Antzelevitch C
    Heart Rhythm; 2015 Jul; 12(7):1584-94. PubMed ID: 25998140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge.
    Priori SG; Napolitano C; Schwartz PJ; Bloise R; Crotti L; Ronchetti E
    Circulation; 2000 Aug; 102(9):945-7. PubMed ID: 10961955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining Cardiomyocyte Repolarization Response to Pharmacotherapy in Long-QT Syndrome Type 3.
    Ge N; Li R; Liu M; Xia W; O'Brien ST; McInerney V; Galvin J; Ward D; McGorrian C; O'Brien T; Shen S; Prendiville TW
    J Am Heart Assoc; 2024 Oct; 13(20):e034690. PubMed ID: 39377211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data.
    Chorin E; Hu D; Antzelevitch C; Hochstadt A; Belardinelli L; Zeltser D; Barajas-Martinez H; Rozovski U; Rosso R; Adler A; Benhorin J; Viskin S
    Circ Arrhythm Electrophysiol; 2016 Oct; 9(10):. PubMed ID: 27733495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-arrhythmic potential of the late sodium current inhibitor GS-458967 in murine Scn5a-1798insD+/- and human SCN5A-1795insD+/- iPSC-derived cardiomyocytes.
    Portero V; Casini S; Hoekstra M; Verkerk AO; Mengarelli I; Belardinelli L; Rajamani S; Wilde AAM; Bezzina CR; Veldkamp MW; Remme CA
    Cardiovasc Res; 2017 Jun; 113(7):829-838. PubMed ID: 28430892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation.
    Windle JR; Geletka RC; Moss AJ; Zareba W; Atkins DL
    Ann Noninvasive Electrocardiol; 2001 Apr; 6(2):153-8. PubMed ID: 11333173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.